HONG KONG – Israel's Can-Fite Biopharma Ltd. has received a first payment of $2 million from CMS Medical Venture Investment Ltd., as part of a recent $72 million development, registration and marketing agreement for the exclusive rights of Can-Fite's lead drug candidates in greater China, an area that includes Hong Kong, Macao and Taiwan.